<DOC>
	<DOCNO>NCT02278614</DOCNO>
	<brief_summary>The objective study assess efficacy safety T2347 ( Latanoprost 0.005 % + Timolol 0.5 % unpreserved eye drop ) versus Xalacom® ocular hypertensive glaucomatous patient initially treat , stabilise Xalacom® generic ( fix combination Latanoprost 0.005 % + Timolol 0.5 % preserve eye drop ) .</brief_summary>
	<brief_title>Efficacy Safety Assessment T2347 Versus Xalacom® Ocular Hypertensive Glaucomatous Patients</brief_title>
	<detailed_description>Phase III , international , multicentre , randomise , investigator mask , 3 month duration , 2 parallel group , 2 X 97 evaluable patient</detailed_description>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Signed date informed consent , Male female age &gt; 18 year old , Both eye open angle glaucoma ocular hypertension already treat control Xalacom® generic ( fix combination Latanoprost 0.005 % + Timolol 0.5 % preserve eye drop ) since least 2 month . IOP ≤ 18 mmHg eye History IOP insufficiently control firstline monotherapy base investigator judgement ( e.g . non reach target IOP ) History addon IOP reduction Xalacom® generic ( fix combination Latanoprost 0.005 % + Timolol 0.5 % preserve eye drop ) comparison firstline treatment Corneal thickness ≥ 500 μm ≤ 600 μm eye . Ophthalmic exclusion criterion ( either eye ) Fundoscopy , VF perform available within 6 month inclusion visit . Significant worsen accord two last VF ( minimum 6 month 2 VF ) Advanced stage glaucoma : Best far correct visual acuity ≤ 1/10 . History trauma , infection , clinically significant inflammation within 3 month inclusion visit . Ongoing known history ocular seasonal perennial allergy ( SAC , PAC ) and/or uveitis and/or viral infection . Presence least one severe objective sign among follow : Hyperaemia ( Grade 5 ) Superficial punctate keratitis ( Grade 3 ) Blepharitis ( Grade 3 ) Severe dry eye ( define severe epithelial erosion cornea and/or use dry eye medication frequency exceed 8 instillation / day ) . Corneal ulceration . Palpebral abnormality relate medical treatment study incompatible good evaluation . History corneal refractive surgery . Any abnormality prevent accurate assessment e.g . reliable tonometry measurement , visual field examination . Systemic/non ophthalmic exclusion criterion Noncontrolled diabetic patient . Reactive airway disease include bronchial asthma history bronchial asthma , severe chronic obstructive pulmonary disease . Sinus bradycardia , sick sinus syndrome , sinoatrial block , second third degree atrioventricular block control pacemaker , overt cardiac failure , cardiogenic shock . Heart rate &lt; 50 bpm , systolic arterial blood pressure≤ 90 mm Hg Known suspect hypersensitivity one component study product . Any medical surgical history , disorder disease acute chronic severe organic disease : hepatic , endocrine , neoplastic , haematological ; immunosuppressive , infectious disease , severe psychiatric illness , relevant cardiovascular abnormality , etc… and/or complicate factor structural abnormality , judge investigator incompatible study . Specific exclusion criterion woman Pregnancy , lactation . Childbearing potential woman use reliable method contraception Exclusion criterion related general condition Inability patient understand study procedure thus inability give informed consent . Noncompliant patient Participation another clinical study investigational drug within last 3 month . Already include study . Patients institutionalised legal regulatory order , inmates psychiatric ward , prison state institution , employee study sit Sponsor 's company . Ward court . Patient covered government health care scheme country ( applicable ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>